The diabetes medical device market encompasses many different categories and sub-categories, and the disease continues to be a major problem. Even though uncertainties continue to plague the healthcare system in the U.S., the market should continue to trend upward in the coming years.
iData Research produces diabetes devices market reports that are unmatched in their depth and accuracy, providing healthcare companies of all sizes the necessary intelligence to help them determine their most effective strategies.
In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international
Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments
In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM in late 2017. Abbott received FDA approval for FreeStyle® Libre in September 2017 and for FreeStyle® Libre 14 Day in July 2018. The
About MedCore Research Our analysts meticulously research for up to 3 to 4 months to put together one suite of reports (MedSuite), which is a comprehensive analysis of a group of healthcare markets. MedCore research is one portion of that analysis that focuses on one market segment and provides further detailed segmentation to get a